AnaptysBio (NASDAQ:ANAB) Stock Price Up 5%

AnaptysBio, Inc. (NASDAQ:ANAB) traded up 5% during trading on Monday . The company traded as high as $33.48 and last traded at $33.47. 179,192 shares changed hands during trading, a decline of 45% from the average session volume of 326,955 shares. The stock had previously closed at $31.87.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ANAB. Wedbush reissued an “outperform” rating and issued a $42.00 price target on shares of AnaptysBio in a research report on Thursday. JPMorgan Chase & Co. boosted their target price on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Truist Financial upped their target price on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $51.10.

AnaptysBio Price Performance

The company has a market capitalization of $915.19 million, a P/E ratio of -5.10 and a beta of -0.29. The stock’s fifty day simple moving average is $35.68 and its 200-day simple moving average is $28.18.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The business had revenue of $10.97 million for the quarter, compared to the consensus estimate of $25.85 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. On average, research analysts predict that AnaptysBio, Inc. will post -6.84 earnings per share for the current year.

Insider Buying and Selling at AnaptysBio

In related news, CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at $189,333.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the sale, the chief financial officer now owns 4,744 shares of the company’s stock, valued at $189,333.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was bought at an average cost of $36.50 per share, for a total transaction of $9,999,978.00. Following the purchase, the insider now owns 7,794,996 shares in the company, valued at $284,517,354. The disclosure for this purchase can be found here. Insiders sold a total of 33,940 shares of company stock valued at $1,251,836 in the last ninety days. Company insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Institutional investors have recently added to or reduced their stakes in the company. Algert Global LLC increased its holdings in AnaptysBio by 11.8% during the 2nd quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock valued at $255,000 after purchasing an additional 1,078 shares in the last quarter. Frazier Life Sciences Management L.P. raised its holdings in shares of AnaptysBio by 140.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock valued at $54,270,000 after buying an additional 1,265,891 shares during the last quarter. Susquehanna Fundamental Investments LLC lifted its position in AnaptysBio by 32.9% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 72,060 shares of the biotechnology company’s stock worth $1,806,000 after buying an additional 17,855 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in AnaptysBio by 49.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 25,312 shares of the biotechnology company’s stock worth $634,000 after acquiring an additional 8,418 shares during the last quarter. Finally, Alpha DNA Investment Management LLC acquired a new stake in AnaptysBio in the 2nd quarter valued at about $399,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.